<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="VYVANSE">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  The following adverse reactions are discussed in greater detail in other sections of the labeling:

 *  Known hypersensitivity to amphetamine products or other ingredients of VYVANSE [see  Contraindications (4)  ]  
 *  Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors [see  Contraindications (4)  and  Drug Interactions (7.1)  ]  
 *  Drug Dependence [see  Boxed Warning  ,  Warnings and Precautions (5.1)  , and  Drug Abuse and Dependence (9.2  ,  9.3)  ]  
 *  Serious Cardiovascular Reactions [see  Warnings and Precautions (5.2)  ]  
 *  Blood Pressure and Heart Rate Increases [see  Warnings and Precautions (5.3)  ]  
 *  Psychiatric Adverse Reactions [see  Warnings and Precautions (5.4)  ]  
 *  Suppression of Growth [see  Warnings and Precautions (5.5)  ]  
 *  Peripheral Vasculopathy, including Raynaud's phenomenon [see  Warnings and Precautions (5.6)  ]  
 *  Serotonin Syndrome [see  Warnings and Precautions (5.7)  ]  
      EXCERPT:   Most common adverse reactions (incidence &gt;=5% and at a rate at least twice placebo) in children, adolescents, and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting (  6.1  )
 

 Most common adverse reactions (incidence &gt;= 5% and at a rate at least twice placebo) in adults with BED were dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety (  6.1  )

   To report SUSPECTED ADVERSE REACTIONS, contact Shire US Inc. at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  

 

  6.1 Clinical Trial Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

     Attention Deficit Hyperactivity Disorder  

 The safety data in this section is based on data from the 4-week parallel-group controlled clinical studies of VYVANSE in pediatric and adult patients with ADHD  [see  Clinical Studies (14.1)  ]  .

     Adverse Reactions Associated with Discontinuation of Treatment in ADHD Clinical Trials  

 In the controlled trial in patients ages 6 to 12 years (Study 1), 8% (18/218) of VYVANSE-treated patients discontinued due to adverse reactions compared to 0% (0/72) of placebo-treated patients. The most frequently reported adverse reactions (1% or more and twice rate of placebo) were ECG voltage criteria for ventricular hypertrophy, tic, vomiting, psychomotor hyperactivity, insomnia, decreased appetite and rash [2 instances for each adverse reaction, i.e., 2/218 (1%)]. Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included abdominal pain upper, dry mouth, weight decreased, dizziness, somnolence, logorrhea, chest pain, anger and hypertension.

 In the controlled trial in patients ages 13 to 17 years (Study 4), 3% (7/233) of VYVANSE-treated patients discontinued due to adverse reactions compared to 1% (1/77) of placebo-treated patients. The most frequently reported adverse reactions (1% or more and twice rate of placebo) were decreased appetite (2/233; 1%) and insomnia (2/233; 1%). Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included irritability, dermatillomania, mood swings, and dyspnea.

 In the controlled adult trial (Study 7), 6% (21/358) of VYVANSE-treated patients discontinued due to adverse reactions compared to 2% (1/62) of placebo-treated patients. The most frequently reported adverse reactions (1% or more and twice rate of placebo) were insomnia (8/358; 2%), tachycardia (3/358; 1%), irritability (2/358; 1%), hypertension (4/358; 1%), headache (2/358; 1%), anxiety (2/358; 1%), and dyspnea (3/358; 1%). Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included palpitations, diarrhea, nausea, decreased appetite, dizziness, agitation, depression, paranoia and restlessness.

     Adverse Reactions Occurring at an Incidence of &gt;=5% or More Among VYVANSE Treated Patients with ADHD in Clinical Trials  

 The most common adverse reactions (incidence &gt;=5% and at a rate at least twice placebo) reported in children, adolescents, and/or adults were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting.

     Adverse Reactions Occurring at an Incidence of 2% or More Among VYVANSE Treated Patients with ADHD in Clinical Trials  

 Adverse reactions reported in the controlled trials in pediatric patients ages 6 to 12 years (Study 1), adolescent patients ages 13 to 17 years (Study 4), and adult patients (Study 7) treated with VYVANSE or placebo are presented in Tables 1, 2, and 3 below.

 Table 1 Adverse Reactions Reported by 2% or More of Children (Ages 6 to 12 Years) with ADHD Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 1) 
                                                     VYVANSE(n=218)                  Placebo(n=72)          
  
 Decreased Appetite                                  39%                             4%                     
 Insomnia                                            22%                             3%                     
 Abdominal Pain Upper                                12%                             6%                     
 Irritability                                        10%                             0%                     
 Vomiting                                            9%                              4%                     
 Weight Decreased                                    9%                              1%                     
 Nausea                                              6%                              3%                     
 Dry Mouth                                           5%                              0%                     
 Dizziness                                           5%                              0%                     
 Affect lability                                     3%                              0%                     
 Rash                                                3%                              0%                     
 Pyrexia                                             2%                              1%                     
 Somnolence                                          2%                              1%                     
 Tic                                                 2%                              0%                     
 Anorexia                                            2%                              0%                     
        Table 2 Adverse Reactions Reported by 2% or More of Adolescent (Ages 13 to 17 Years) Patients with ADHD Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 4) 
                                                     VYVANSE(n=233)                  Placebo(n=77)          
  
 Decreased Appetite                                  34%                             3%                     
 Insomnia                                            13%                             4%                     
 Weight Decreased                                    9%                              0%                     
 Dry Mouth                                           4%                              1%                     
 Palpitations                                        2%                              1%                     
 Anorexia                                            2%                              0%                     
 Tremor                                              2%                              0%                     
        Table 3 Adverse Reactions Reported by 2% or More of Adult Patients with ADHD Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 7) 
                                                     VYVANSE(n=358)                  Placebo(n=62)          
  
 Decreased Appetite                                  27%                             2%                     
 Insomnia                                            27%                             8%                     
 Dry Mouth                                           26%                             3%                     
 Diarrhea                                            7%                              0%                     
 Nausea                                              7%                              0%                     
 Anxiety                                             6%                              0%                     
 Anorexia                                            5%                              0%                     
 Feeling Jittery                                     4%                              0%                     
 Agitation                                           3%                              0%                     
 Increased Blood Pressure                            3%                              0%                     
 Hyperhidrosis                                       3%                              0%                     
 Restlessness                                        3%                              0%                     
 Decreased Weight                                    3%                              0%                     
 Dyspnea                                             2%                              0%                     
 Increased Heart Rate                                2%                              0%                     
 Tremor                                              2%                              0%                     
 Palpitations                                        2%                              0%                     
         In addition, in the adult population erectile dysfunction was observed in 2.6% of males on VYVANSE and 0% on placebo; decreased libido was observed in 1.4% of subjects on VYVANSE and 0% on placebo.
 

     Weight Loss and Slowing Growth Rate in Pediatric Patients with ADHD  

 In a controlled trial of VYVANSE in children ages 6 to 12 years (Study 1), mean weight loss from baseline after 4 weeks of therapy was -0.9, -1.9, and -2.5 pounds, respectively, for patients receiving 30 mg, 50 mg, and 70 mg of VYVANSE, compared to a 1 pound weight gain for patients receiving placebo. Higher doses were associated with greater weight loss with 4 weeks of treatment. Careful follow-up for weight in children ages 6 to 12 years who received VYVANSE over 12 months suggests that consistently medicated children (i.e. treatment for 7 days per week throughout the year) have a slowing in growth rate, measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and 47.2, respectively). In a 4-week controlled trial of VYVANSE in adolescents ages 13 to 17 years, mean weight loss from baseline to endpoint was -2.7, -4.3, and -4.8 lbs., respectively, for patients receiving 30 mg, 50 mg, and 70 mg of VYVANSE, compared to a 2.0 pound weight gain for patients receiving placebo.

 Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e. treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. In a controlled trial of amphetamine (d- to l-enantiomer ratio of 3:1) in adolescents, mean weight change from baseline within the initial 4 weeks of therapy was -1.1 pounds and -2.8 pounds, respectively, for patients receiving 10 mg and 20 mg of amphetamine. Higher doses were associated with greater weight loss within the initial 4 weeks of treatment  [see  Warnings and Precautions (5.5)  ]  .

     Weight Loss in Adults with ADHD  

 In the controlled adult trial (Study 7), mean weight loss after 4 weeks of therapy was 2.8 pounds, 3.1 pounds, and 4.3 pounds, for patients receiving final doses of 30 mg, 50 mg, and 70 mg of VYVANSE, respectively, compared to a mean weight gain of 0.5 pounds for patients receiving placebo.

     Binge Eating Disorder  

 The safety data in this section is based on data from two 12 week parallel group, flexible-dose, placebo-controlled studies in adults with BED  [see  Clinical Studies 14.2  ]  . Patients with cardiovascular risk factors other than obesity and smoking were excluded.

     Adverse Reactions Associated with Discontinuation of Treatment in BED Clinical Trials  

 In controlled trials of patients ages 18 to 55 years, 5.1% (19/373) of VYVANSE-treated patients discontinued due to adverse reactions compared to 2.4% (9/372) of placebo-treated patients. No single adverse reaction led to discontinuation in 1% or more of VYVANSE-treated patients. Less commonly reported adverse reactions (less than 1% or less than twice rate of placebo) included increased heart rate, headache, abdominal pain upper, dyspnea, rash, insomnia, irritability, feeling jittery and anxiety.

 The most common adverse reactions (incidence &gt;=5% and at a rate at least twice placebo) reported in adults were dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety.

 Adverse reactions reported in the pooled controlled trials in adult patients (Study 11 and 12) treated with VYVANSE or placebo are presented in Table 4 below.

 Table 4 Adverse Reactions Reported by 2% or More of Adult Patients with BED Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in 12-Week Clinical Trials (Study 11 and 12) 
                                                             VYVANSE(N=373)             Placebo(N=372)      
  
 Dry Mouth                                                        36%                         7%            
 Insomnia [note: Includes all preferred terms containing the word "insomnia."]                20%                         8%            
 Decreased Appetite                                                8%                         2%            
 Increased Heart Rate [note: Includes the preferred terms "heart rate increased" and "tachycardia."]                 7%                         1%            
 Feeling Jittery                                                   6%                         1%            
 Constipation                                                      6%                         1%            
 Anxiety                                                           5%                         1%            
 Diarrhea                                                          4%                         2%            
 Decreased Weight                                                  4%                         0%            
 Hyperhidrosis                                                     4%                         0%            
 Vomiting                                                          2%                         1%            
 Gastroenteritis                                                   2%                         1%            
 Paresthesia                                                       2%                         1%            
 Pruritis                                                          2%                         1%            
 Upper Abdominal Pain                                              2%                         0%            
 Energy Increased                                                  2%                         0%            
 Urinary Tract Infection                                           2%                         0%            
 Nightmare                                                         2%                         0%            
 Restlessness                                                      2%                         0%            
 Oropharyngeal Pain                                                2%                         0%            
           6.2 Postmarketing Experience
   The following adverse reactions have been identified during post approval use of VYVANSE. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events are as follows: cardiomyopathy, mydriasis, diplopia, difficulties with visual accommodation, blurred vision, eosinophilic hepatitis, anaphylactic reaction, hypersensitivity, dyskinesia, dysgeusia, tics, bruxism, depression, dermatillomania, alopecia, aggression, Stevens-Johnson Syndrome, chest pain, angioedema, urticaria, seizures, libido changes, frequent or prolonged erections, constipation, and rhabdomyolysis.

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING:  ABUSE AND DEPENDENCE

    WARNING:  ABUSE AND DEPENDENCE  

    CNS stimulants (amphetamines and methylphenidate-containing products), including VYVANSE, have a high potential for abuse and dependence.  Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy     [see   Warnings and Precautions (5.1  ,   5.2)  , and   Drug Abuse and Dependence (9.2  ,   9.3)  ].  

   EXCERPT:   WARNING:  ABUSE  AND DEPENDENCE

   See full prescribing information for complete boxed warning.  

 *  CNS stimulants (amphetamines and methylphenidate-containing products), including VYVANSE, have a high potential for abuse and dependence (5.1, 9.2, 9.3) 
 *  Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy (5.1, 9.2) 
    

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *   Serious Cardiovascular Reactions: Sudden death has been reported in association with CNS stimulant treatment at recommended doses in pediatric patients with structural cardiac abnormalities or other serious heart problems. In adults, sudden death, stroke, and myocardial infarction have been reported. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, or coronary artery disease (  5.2  ) 
 *   Blood Pressure and Heart Rate Increases: Monitor blood pressure and pulse. Consider benefits and risks before use in patients for whom blood pressure increases may be problematic (  5.3  ) 
 *   Psychiatric Adverse Reactions: May cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis. Evaluate for bipolar disorder prior to stimulant use (  5.4  ) 
 *   Suppression of Growth: Monitor height and weight in pediatric patients during treatment (  5.5  ) 
 *   Peripheral Vasculopathy, including Raynaud's phenomenon: Stimulants are associated with peripheral vasculopathy, including Raynaud's phenomenon. Careful observation for digital changes is necessary during treatment with stimulants (  5.6  ) 
 *   Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. If it occurs, discontinue VYVANSE and initiate supportive treatment (  4  ,  5.7  ,  10  ). 
    
 

   5.1 Potential for Abuse and Dependence

  CNS stimulants (amphetamines and methylphenidate-containing products), including VYVANSE, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see  Drug Abuse and Dependence (9.2  ,  9.3)  ]  .

    5.2 Serious Cardiovascular Reactions

  Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulant treatment at recommended doses. Sudden death has been reported in children and adolescents with structural cardiac abnormalities and other serious heart problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during VYVANSE treatment.

    5.3 Blood Pressure and Heart Rate Increases

  CNS stimulants cause an increase in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for potential tachycardia and hypertension.

    5.4 Psychiatric Adverse Reactions

   Exacerbation of Pre-existing Psychosis  

 CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.

     Induction of a Manic Episode in Patients with Bipolar Disorder    

  CNS stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  

    New Psychotic or Manic Symptoms  

 CNS stimulants, at recommended doses, may cause psychotic or manic symptoms, e.g. hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing VYVANSE. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in 0.1% of CNS stimulant-treated patients compared to 0% in placebo-treated patients.

    5.5 Suppression of Growth

  CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Closely monitor growth (weight and height) in pediatric patients treated with CNS stimulants, including VYVANSE. In a 4-week, placebo-controlled trial of VYVANSE in patients ages 6 to 12 years old with ADHD, there was a dose-related decrease in weight in the VYVANSE groups compared to weight gain in the placebo group. Additionally, in studies of another stimulant, there was slowing of the increase in height [see  Adverse Reactions (6.1)  ]  .

    5.6 Peripheral Vasculopathy, including Raynaud's Phenomenon

  Stimulants, including VYVANSE, are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

    5.7 Serotonin Syndrome

   Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort [see  Drug Interactions (7.1)  ]  . Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism [see  Clinical Pharmacology 12.3  ]  . The potential for a pharmacokinetic interaction exists with the co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to the active metabolite of VYVANSE (dextroamphetamine). In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 [see  Drug Interactions (7.1)  ]  . Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).  

  Concomitant use of VYVANSE with MAOI drugs is contraindicated [see  Contraindications (4)  ]  .  

  Discontinue treatment with VYVANSE and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. Concomitant use of VYVANSE with other serotonergic drugs or CYP2D6 inhibitors should be used only if the potential benefit justifies the potential risk. If clinically warranted, consider initiating VYVANSE with lower doses, monitoring patients for the emergence of serotonin syndrome during drug initiation or titration, and informing patients of the increased risk for serotonin syndrome.  

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="1508" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="34" name="heading" section="S2" start="55" />
    <IgnoredRegion len="399" name="excerpt" section="S2" start="453" />
    <IgnoredRegion len="682" name="excerpt" section="S1" start="995" />
    <IgnoredRegion len="38" name="heading" section="S3" start="1548" />
    <IgnoredRegion len="29" name="heading" section="S1" start="1681" />
    <IgnoredRegion len="36" name="heading" section="S3" start="1895" />
    <IgnoredRegion len="43" name="heading" section="S3" start="2541" />
    <IgnoredRegion len="33" name="heading" section="S3" start="2787" />
    <IgnoredRegion len="25" name="heading" section="S3" start="3904" />
    <IgnoredRegion len="59" name="heading" section="S3" start="4488" />
    <IgnoredRegion len="22" name="heading" section="S3" start="5284" />
    <IgnoredRegion len="28" name="heading" section="S1" start="16842" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M170" len="16" reason="from_drug_use" section="S1" start="135" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M6" len="19" reason="AE_from_drug_interaction" section="S1" start="245" type="NonOSE_AE">
      <Normalization meddra_llt="Crisis hypertensive" meddra_llt_id="10011395" meddra_pt="Hypertensive crisis" meddra_pt_id="10020802" />
    </Mention>
    <Mention id="M171" len="15" reason="from_drug_use" section="S1" start="390" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug dependence" meddra_llt_id="10013663" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M172" len="24" reason="class_effect" section="S1" start="526" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M185" len="14,9" reason="from_drug_use" section="S1" start="597,627" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pressure blood increased" meddra_llt_id="10036640" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M173" len="20" reason="class_effect" section="S1" start="616" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate high" meddra_llt_id="10019302" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M174" len="29" reason="class_effect" section="S1" start="683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M11" len="21" reason="from_drug_use" section="S1" start="759" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth suppression" meddra_llt_id="10018761" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M12" len="23" reason="from_drug_use" section="S1" start="827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Poor peripheral circ" meddra_llt_id="10036154" meddra_pt="Poor peripheral circulation" meddra_pt_id="10036155" />
    </Mention>
    <Mention id="M184" len="20" reason="from_drug_use" section="S1" start="862" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Raynaud's phenomenon" meddra_llt_id="10037912" meddra_pt="Raynaud's phenomenon" meddra_pt_id="10037912" />
    </Mention>
    <Mention id="M7" len="18" reason="AE_from_drug_interaction" section="S1" start="929" type="NonOSE_AE">
      <Normalization meddra_llt="Serotonin syndrome" meddra_llt_id="10040108" meddra_pt="Serotonin syndrome" meddra_pt_id="10040108" />
    </Mention>
    <Mention id="M1" len="40" reason="indication" section="S1" start="1984" type="Not_AE_Candidate">
      <Normalization meddra_llt="Attention deficit-hyperactivity disorder" meddra_llt_id="10003735" meddra_pt="Attention deficit/hyperactivity disorder" meddra_pt_id="10003736" />
    </Mention>
    <Mention id="M2" len="4" reason="indication" section="S1" start="2185" type="Not_AE_Candidate">
      <Normalization meddra_llt="ADHD" meddra_llt_id="10064104" meddra_pt="Attention deficit/hyperactivity disorder" meddra_pt_id="10003736" />
    </Mention>
    <Mention id="M13" len="48" reason="from_drug_use" section="S1" start="2610" type="OSE_Labeled_AE">
      <Normalization meddra_llt="ECG signs of ventricular hypertrophy" meddra_llt_id="10050998" meddra_pt="ECG signs of ventricular hypertrophy" meddra_pt_id="10050998" />
    </Mention>
    <Mention id="M14" len="3" reason="from_drug_use" section="S1" start="2660" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tic" meddra_llt_id="10043833" meddra_pt="Tic" meddra_pt_id="10043833" />
    </Mention>
    <Mention id="M15" len="8" reason="from_drug_use" section="S1" start="2665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M16" len="25" reason="from_drug_use" section="S1" start="2675" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychomotor hyperactivity" meddra_llt_id="10037211" meddra_pt="Psychomotor hyperactivity" meddra_pt_id="10037211" />
    </Mention>
    <Mention id="M17" len="8" reason="from_drug_use" section="S1" start="2702" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M18" len="18" reason="from_drug_use" section="S1" start="2712" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M19" len="4" reason="from_drug_use" section="S1" start="2735" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M20" len="20" reason="from_drug_use" section="S1" start="2901" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M21" len="9" reason="from_drug_use" section="S1" start="2923" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M22" len="16" reason="from_drug_use" section="S1" start="2934" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M23" len="9" reason="from_drug_use" section="S1" start="2952" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M24" len="10" reason="from_drug_use" section="S1" start="2963" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M25" len="9" reason="from_drug_use" section="S1" start="2975" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Logorrhea" meddra_llt_id="10062848" meddra_pt="Logorrhoea" meddra_pt_id="10024796" />
    </Mention>
    <Mention id="M26" len="10" reason="from_drug_use" section="S1" start="2986" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M27" len="5" reason="from_drug_use" section="S1" start="2998" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anger" meddra_llt_id="10002368" meddra_pt="Anger" meddra_pt_id="10002368" />
    </Mention>
    <Mention id="M28" len="12" reason="from_drug_use" section="S1" start="3008" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M29" len="18" reason="from_drug_use" section="S1" start="3310" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M30" len="8" reason="from_drug_use" section="S1" start="3345" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M31" len="12" reason="from_drug_use" section="S1" start="3469" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M32" len="15" reason="from_drug_use" section="S1" start="3483" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatillomania" meddra_llt_id="10065701" meddra_pt="Dermatillomania" meddra_pt_id="10065701" />
    </Mention>
    <Mention id="M33" len="11" reason="from_drug_use" section="S1" start="3500" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mood swings" meddra_llt_id="10027951" meddra_pt="Mood swings" meddra_pt_id="10027951" />
    </Mention>
    <Mention id="M34" len="7" reason="from_drug_use" section="S1" start="3517" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M35" len="8" reason="from_drug_use" section="S1" start="3789" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M36" len="11" reason="from_drug_use" section="S1" start="3811" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M37" len="12" reason="from_drug_use" section="S1" start="3836" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M175" len="12" reason="from_drug_use" section="S1" start="3862" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M38" len="8" reason="from_drug_use" section="S1" start="3888" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M39" len="7" reason="from_drug_use" section="S1" start="3910" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M40" len="7" reason="from_drug_use" section="S1" start="3935" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M41" len="12" reason="from_drug_use" section="S1" start="4058" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M42" len="8" reason="from_drug_use" section="S1" start="4072" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M43" len="6" reason="from_drug_use" section="S1" start="4082" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M44" len="18" reason="from_drug_use" section="S1" start="4090" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M45" len="9" reason="from_drug_use" section="S1" start="4110" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M46" len="9" reason="from_drug_use" section="S1" start="4121" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M47" len="10" reason="from_drug_use" section="S1" start="4132" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M48" len="8" reason="from_drug_use" section="S1" start="4144" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paranoia" meddra_llt_id="10033864" meddra_pt="Paranoia" meddra_pt_id="10033864" />
    </Mention>
    <Mention id="M49" len="12" reason="from_drug_use" section="S1" start="4157" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M50" len="8" reason="from_drug_use" section="S1" start="4443" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M51" len="7" reason="from_drug_use" section="S1" start="4453" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M52" len="18" reason="from_drug_use" section="S1" start="4462" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M53" len="16" reason="from_drug_use" section="S1" start="4482" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M54" len="8" reason="from_drug_use" section="S1" start="4500" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M55" len="9" reason="from_drug_use" section="S1" start="4510" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M56" len="9" reason="from_drug_use" section="S1" start="4521" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M57" len="12" reason="from_drug_use" section="S1" start="4532" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M58" len="8" reason="from_drug_use" section="S1" start="4546" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M59" len="6" reason="from_drug_use" section="S1" start="4556" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M60" len="20" reason="from_drug_use" section="S1" start="4564" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M61" len="8" reason="from_drug_use" section="S1" start="4590" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M62" len="18" reason="from_drug_use" section="S1" start="5307" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M63" len="8" reason="from_drug_use" section="S1" start="5416" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M64" len="20" reason="from_drug_use" section="S1" start="5525" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M65" len="12" reason="from_drug_use" section="S1" start="5634" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M66" len="8" reason="from_drug_use" section="S1" start="5743" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M67" len="16" reason="from_drug_use" section="S1" start="5852" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M68" len="6" reason="from_drug_use" section="S1" start="5961" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M69" len="9" reason="from_drug_use" section="S1" start="6070" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M70" len="9" reason="from_drug_use" section="S1" start="6179" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M71" len="15" reason="from_drug_use" section="S1" start="6288" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Affect lability" meddra_llt_id="10054196" meddra_pt="Affect lability" meddra_pt_id="10054196" />
    </Mention>
    <Mention id="M72" len="4" reason="from_drug_use" section="S1" start="6397" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M73" len="7" reason="from_drug_use" section="S1" start="6506" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyrexia" meddra_llt_id="10037660" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M74" len="10" reason="from_drug_use" section="S1" start="6615" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M75" len="3" reason="from_drug_use" section="S1" start="6724" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tic" meddra_llt_id="10043833" meddra_pt="Tic" meddra_pt_id="10043833" />
    </Mention>
    <Mention id="M76" len="8" reason="from_drug_use" section="S1" start="6833" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M77" len="18" reason="from_drug_use" section="S1" start="7279" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M78" len="8" reason="from_drug_use" section="S1" start="7388" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M79" len="16" reason="from_drug_use" section="S1" start="7497" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M80" len="9" reason="from_drug_use" section="S1" start="7606" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M81" len="12" reason="from_drug_use" section="S1" start="7715" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M82" len="8" reason="from_drug_use" section="S1" start="7824" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M83" len="6" reason="from_drug_use" section="S1" start="7933" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M84" len="18" reason="from_drug_use" section="S1" start="8352" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M85" len="8" reason="from_drug_use" section="S1" start="8461" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M86" len="9" reason="from_drug_use" section="S1" start="8570" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M87" len="8" reason="from_drug_use" section="S1" start="8679" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M88" len="6" reason="from_drug_use" section="S1" start="8788" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M89" len="7" reason="from_drug_use" section="S1" start="8897" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M90" len="8" reason="from_drug_use" section="S1" start="9006" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M91" len="15" reason="from_drug_use" section="S1" start="9115" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Feeling jittery" meddra_llt_id="10016338" meddra_pt="Feeling jittery" meddra_pt_id="10016338" />
    </Mention>
    <Mention id="M92" len="9" reason="from_drug_use" section="S1" start="9224" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M93" len="24" reason="from_drug_use" section="S1" start="9333" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pressure blood increased" meddra_llt_id="10036640" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M94" len="13" reason="from_drug_use" section="S1" start="9442" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperhidrosis" meddra_llt_id="10020642" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M95" len="12" reason="from_drug_use" section="S1" start="9551" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M96" len="16" reason="from_drug_use" section="S1" start="9660" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M97" len="7" reason="from_drug_use" section="S1" start="9769" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M98" len="20" reason="from_drug_use" section="S1" start="9878" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate increased" meddra_llt_id="10019303" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M99" len="6" reason="from_drug_use" section="S1" start="9987" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M100" len="12" reason="from_drug_use" section="S1" start="10096" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M101" len="20" reason="from_drug_use" section="S1" start="10250" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erectile dysfunction" meddra_llt_id="10061461" meddra_pt="Erectile dysfunction" meddra_pt_id="10061461" />
    </Mention>
    <Mention id="M102" len="16" reason="from_drug_use" section="S1" start="10331" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Libido decreased" meddra_llt_id="10024419" meddra_pt="Libido decreased" meddra_pt_id="10024419" />
    </Mention>
    <Mention id="M176" len="11" reason="from_drug_use" section="S1" start="10571" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M8" len="11" reason="AE_only_as_instruction" section="S1" start="10750" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M103" len="11" reason="from_drug_use" section="S1" start="10836" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M104" len="22" reason="from_drug_use" section="S1" start="11081" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M177" len="11" reason="from_drug_use" section="S1" start="11400" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M9" len="11" reason="AE_only_as_instruction" section="S1" start="11566" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M105" len="22" reason="from_drug_use" section="S1" start="12053" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M178" len="26" reason="from_drug_use" section="S1" start="12106" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M179" len="28" reason="from_drug_use" section="S1" start="12137" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M180" len="13" reason="from_drug_use" section="S1" start="12343" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight abnormal" meddra_llt_id="10056814" meddra_pt="Weight abnormal" meddra_pt_id="10056814" />
    </Mention>
    <Mention id="M106" len="11" reason="from_drug_use" section="S1" start="12553" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M107" len="11" reason="from_drug_use" section="S1" start="12737" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M10" len="11" reason="AE_only_as_instruction" section="S1" start="12925" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M3" len="21" reason="indication" section="S1" start="12989" type="Not_AE_Candidate">
      <Normalization meddra_llt="Binge eating" meddra_llt_id="10004716" meddra_pt="Binge eating" meddra_pt_id="10004716" />
    </Mention>
    <Mention id="M4" len="3" reason="indication" section="S1" start="13154" type="Not_AE_Candidate">
      <Normalization meddra_llt="Binge eating" meddra_llt_id="10004716" meddra_pt="Binge eating" meddra_pt_id="10004716" />
    </Mention>
    <Mention id="M5" len="7" reason="preexisting_condition_or_risk_factor" section="S1" start="13246" type="Not_AE_Candidate">
      <Normalization meddra_llt="Obesity" meddra_llt_id="10029883" meddra_pt="Obesity" meddra_pt_id="10029883" />
    </Mention>
    <Mention id="M108" len="20" reason="from_drug_use" section="S1" start="13758" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate increased" meddra_llt_id="10019303" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M109" len="8" reason="from_drug_use" section="S1" start="13780" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M110" len="20" reason="from_drug_use" section="S1" start="13790" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M111" len="7" reason="from_drug_use" section="S1" start="13812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M112" len="4" reason="from_drug_use" section="S1" start="13821" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M113" len="8" reason="from_drug_use" section="S1" start="13827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M114" len="12" reason="from_drug_use" section="S1" start="13837" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M115" len="15" reason="from_drug_use" section="S1" start="13851" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Feeling jittery" meddra_llt_id="10016338" meddra_pt="Feeling jittery" meddra_pt_id="10016338" />
    </Mention>
    <Mention id="M181" len="7" reason="from_drug_use" section="S1" start="13871" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M116" len="9" reason="from_drug_use" section="S1" start="13994" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M117" len="8" reason="from_drug_use" section="S1" start="14005" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M118" len="18" reason="from_drug_use" section="S1" start="14015" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M119" len="20" reason="from_drug_use" section="S1" start="14035" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate increased" meddra_llt_id="10019303" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M120" len="12" reason="from_drug_use" section="S1" start="14057" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M121" len="15" reason="from_drug_use" section="S1" start="14071" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Feeling jittery" meddra_llt_id="10016338" meddra_pt="Feeling jittery" meddra_pt_id="10016338" />
    </Mention>
    <Mention id="M122" len="7" reason="from_drug_use" section="S1" start="14092" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M123" len="9" reason="from_drug_use" section="S1" start="14574" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M124" len="8" reason="from_drug_use" section="S1" start="14683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M182" len="9" reason="from_drug_use" section="S1" start="14748" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M125" len="18" reason="from_drug_use" section="S1" start="14820" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M126" len="20" reason="from_drug_use" section="S1" start="14929" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate increased" meddra_llt_id="10019303" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M127" len="20" reason="from_drug_use" section="S1" start="14987" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate increased" meddra_llt_id="10019303" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M128" len="11" reason="from_drug_use" section="S1" start="15014" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M129" len="15" reason="from_drug_use" section="S1" start="15088" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Feeling jittery" meddra_llt_id="10016338" meddra_pt="Feeling jittery" meddra_pt_id="10016338" />
    </Mention>
    <Mention id="M130" len="12" reason="from_drug_use" section="S1" start="15197" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M131" len="7" reason="from_drug_use" section="S1" start="15306" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M132" len="8" reason="from_drug_use" section="S1" start="15415" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M133" len="16" reason="from_drug_use" section="S1" start="15524" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M134" len="13" reason="from_drug_use" section="S1" start="15633" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperhidrosis" meddra_llt_id="10020642" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M135" len="8" reason="from_drug_use" section="S1" start="15742" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M136" len="15" reason="from_drug_use" section="S1" start="15851" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis" meddra_llt_id="10017888" meddra_pt="Gastroenteritis" meddra_pt_id="10017888" />
    </Mention>
    <Mention id="M137" len="11" reason="from_drug_use" section="S1" start="15960" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M138" len="8" reason="from_drug_use" section="S1" start="16069" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritis" meddra_llt_id="10037086" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M139" len="20" reason="from_drug_use" section="S1" start="16178" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M140" len="16" reason="from_drug_use" section="S1" start="16287" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Energy increased" meddra_llt_id="10048779" meddra_pt="Energy increased" meddra_pt_id="10048779" />
    </Mention>
    <Mention id="M141" len="23" reason="from_drug_use" section="S1" start="16396" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection urinary tract" meddra_llt_id="10021872" meddra_pt="Urinary tract infection" meddra_pt_id="10046571" />
    </Mention>
    <Mention id="M142" len="9" reason="from_drug_use" section="S1" start="16505" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nightmare" meddra_llt_id="10029412" meddra_pt="Nightmare" meddra_pt_id="10029412" />
    </Mention>
    <Mention id="M143" len="12" reason="from_drug_use" section="S1" start="16614" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M144" len="18" reason="from_drug_use" section="S1" start="16723" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oropharyngeal pain" meddra_llt_id="10068319" meddra_pt="Oropharyngeal pain" meddra_pt_id="10068319" />
    </Mention>
    <Mention id="M145" len="14" reason="from_drug_use" section="S1" start="17188" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiomyopathy" meddra_llt_id="10007636" meddra_pt="Cardiomyopathy" meddra_pt_id="10007636" />
    </Mention>
    <Mention id="M146" len="9" reason="from_drug_use" section="S1" start="17204" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mydriasis" meddra_llt_id="10028521" meddra_pt="Mydriasis" meddra_pt_id="10028521" />
    </Mention>
    <Mention id="M147" len="8" reason="from_drug_use" section="S1" start="17215" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diplopia" meddra_llt_id="10013036" meddra_pt="Diplopia" meddra_pt_id="10013036" />
    </Mention>
    <Mention id="M148" len="38" reason="from_drug_use" section="S1" start="17225" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Visual accommodation disturbance of" meddra_llt_id="10047528" meddra_pt="Accommodation disorder" meddra_pt_id="10000389" />
    </Mention>
    <Mention id="M149" len="14" reason="from_drug_use" section="S1" start="17265" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M150" len="22" reason="from_drug_use" section="S1" start="17281" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatitis" meddra_llt_id="10019717" meddra_pt="Hepatitis" meddra_pt_id="10019717" />
    </Mention>
    <Mention id="M151" len="21" reason="from_drug_use" section="S1" start="17305" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylactic reaction" meddra_llt_id="10002198" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M152" len="16" reason="from_drug_use" section="S1" start="17328" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M153" len="10" reason="from_drug_use" section="S1" start="17346" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia" meddra_llt_id="10013916" meddra_pt="Dyskinesia" meddra_pt_id="10013916" />
    </Mention>
    <Mention id="M154" len="9" reason="from_drug_use" section="S1" start="17358" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysgeusia" meddra_llt_id="10013911" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M155" len="4" reason="from_drug_use" section="S1" start="17369" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tics" meddra_llt_id="10043849" meddra_pt="Tic" meddra_pt_id="10043833" />
    </Mention>
    <Mention id="M156" len="7" reason="from_drug_use" section="S1" start="17375" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bruxism" meddra_llt_id="10006514" meddra_pt="Bruxism" meddra_pt_id="10006514" />
    </Mention>
    <Mention id="M157" len="10" reason="from_drug_use" section="S1" start="17384" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M158" len="15" reason="from_drug_use" section="S1" start="17396" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatillomania" meddra_llt_id="10065701" meddra_pt="Dermatillomania" meddra_pt_id="10065701" />
    </Mention>
    <Mention id="M159" len="8" reason="from_drug_use" section="S1" start="17413" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M160" len="10" reason="from_drug_use" section="S1" start="17423" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aggression" meddra_llt_id="10001488" meddra_pt="Aggression" meddra_pt_id="10001488" />
    </Mention>
    <Mention id="M161" len="24" reason="from_drug_use" section="S1" start="17435" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M162" len="10" reason="from_drug_use" section="S1" start="17461" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M163" len="10" reason="from_drug_use" section="S1" start="17473" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M164" len="9" reason="from_drug_use" section="S1" start="17485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urticaria" meddra_llt_id="10046735" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M165" len="8" reason="from_drug_use" section="S1" start="17496" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M166" len="14" reason="from_drug_use" section="S1" start="17506" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Libido disorder" meddra_llt_id="10061221" meddra_pt="Libido disorder" meddra_pt_id="10061221" />
    </Mention>
    <Mention id="M183" len="8,9" reason="from_drug_use" section="S1" start="17522,17544" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spontaneous penile erection" meddra_llt_id="10049118" meddra_pt="Spontaneous penile erection" meddra_pt_id="10049118" />
    </Mention>
    <Mention id="M167" len="19" reason="from_drug_use" section="S1" start="17534" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erection prolonged" meddra_llt_id="10068039" meddra_pt="Erection increased" meddra_pt_id="10015120" />
    </Mention>
    <Mention id="M168" len="12" reason="from_drug_use" section="S1" start="17555" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M169" len="14" reason="from_drug_use" section="S1" start="17573" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhabdomyolysis" meddra_llt_id="10039020" meddra_pt="Rhabdomyolysis" meddra_pt_id="10039020" />
    </Mention>
    <Mention id="M192" len="5" reason="from_drug_use" section="S2" start="211" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug abuse" meddra_llt_id="10013654" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M191" len="10" reason="from_drug_use" section="S2" start="221" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cannabis dependence" meddra_llt_id="10007177" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M186" len="5" reason="AE_only_as_instruction" section="S2" start="253" type="NonOSE_AE">
      <Normalization meddra_llt="Analgesic abuse" meddra_llt_id="10002186" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M188" len="5" reason="AE_only_as_instruction" section="S2" start="305" type="NonOSE_AE">
      <Normalization meddra_llt="Analgesic abuse" meddra_llt_id="10002186" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M189" len="10" reason="AE_only_as_instruction" section="S2" start="315" type="NonOSE_AE">
      <Normalization meddra_llt="Cannabis dependence" meddra_llt_id="10007177" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M187" len="10" reason="AE_only_as_instruction" section="S2" start="403" type="NonOSE_AE">
      <Normalization meddra_llt="Drug abuse" meddra_llt_id="10013654" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M190" len="10" reason="AE_only_as_instruction" section="S2" start="418" type="NonOSE_AE">
      <Normalization meddra_llt="Cannabis dependence" meddra_llt_id="10007177" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M281" len="5" reason="from_drug_use" section="S3" start="1706" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug abuse" meddra_llt_id="10013654" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M253" len="10" reason="from_drug_use" section="S3" start="1716" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cannabis dependence" meddra_llt_id="10007177" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M215" len="5" reason="AE_only_as_instruction" section="S3" start="1747" type="NonOSE_AE">
      <Normalization meddra_llt="Analgesic abuse" meddra_llt_id="10002186" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M216" len="5" reason="AE_only_as_instruction" section="S3" start="1800" type="NonOSE_AE">
      <Normalization meddra_llt="Analgesic abuse" meddra_llt_id="10002186" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M217" len="10" reason="AE_only_as_instruction" section="S3" start="1810" type="NonOSE_AE">
      <Normalization meddra_llt="Cannabis dependence" meddra_llt_id="10007177" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M218" len="10" reason="AE_only_as_instruction" section="S3" start="1844" type="NonOSE_AE">
      <Normalization meddra_llt="Drug abuse" meddra_llt_id="10013654" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M219" len="10" reason="AE_only_as_instruction" section="S3" start="1859" type="NonOSE_AE">
      <Normalization meddra_llt="Cannabis dependence" meddra_llt_id="10007177" meddra_pt="Drug dependence" meddra_pt_id="10013663" />
    </Mention>
    <Mention id="M259" len="24" reason="class_effect" section="S3" start="1907" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M260" len="12" reason="class_effect" section="S3" start="1935" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sudden death" meddra_llt_id="10042434" meddra_pt="Sudden death" meddra_pt_id="10042434" />
    </Mention>
    <Mention id="M261" len="6" reason="class_effect" section="S3" start="1949" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M262" len="21" reason="class_effect" section="S3" start="1960" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M263" len="12" reason="class_effect" section="S3" start="2062" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sudden death" meddra_llt_id="10042434" meddra_pt="Sudden death" meddra_pt_id="10042434" />
    </Mention>
    <Mention id="M193" len="32" reason="preexisting_condition_or_risk_factor" section="S3" start="2126" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M203" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="2177" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M194" len="4" reason="indication" section="S3" start="2239" type="Not_AE_Candidate">
      <Normalization meddra_llt="ADHD" meddra_llt_id="10064104" meddra_pt="Attention deficit/hyperactivity disorder" meddra_pt_id="10003736" />
    </Mention>
    <Mention id="M195" len="32" reason="preexisting_condition_or_risk_factor" section="S3" start="2278" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M196" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="2312" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiomyopathy" meddra_llt_id="10007636" meddra_pt="Cardiomyopathy" meddra_pt_id="10007636" />
    </Mention>
    <Mention id="M197" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="2336" type="Not_AE_Candidate">
      <Normalization meddra_llt="Arrhythmia" meddra_llt_id="10003119" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M198" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="2354" type="Not_AE_Candidate">
      <Normalization meddra_llt="Coronary artery disease" meddra_llt_id="10011078" meddra_pt="Coronary artery disease" meddra_pt_id="10011078" />
    </Mention>
    <Mention id="M204" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="2397" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M209" len="21" reason="manifestation_or_complication" section="S3" start="2451" type="NonOSE_AE">
      <Normalization meddra_llt="Chest pain exertional" meddra_llt_id="10059064" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M210" len="19" reason="manifestation_or_complication" section="S3" start="2474" type="NonOSE_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M211" len="11" reason="manifestation_or_complication" section="S3" start="2498" type="NonOSE_AE">
      <Normalization meddra_llt="Arrhythmia" meddra_llt_id="10003119" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M264" len="26" reason="class_effect" section="S3" start="2612" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transient blood pressure increase" meddra_llt_id="10074450" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M265" len="8,10" reason="from_drug_use" section="S3" start="2612,2675" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate high" meddra_llt_id="10019302" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M220" len="11" reason="manifestation_or_complication" section="S3" start="2752" type="NonOSE_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M221" len="12" reason="manifestation_or_complication" section="S3" start="2768" type="NonOSE_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M280" len="29" reason="class_effect" section="S3" start="2791" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M266" len="38" reason="class_effect" section="S3" start="2825" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychosis" meddra_llt_id="10037234" meddra_pt="Psychotic disorder" meddra_pt_id="10061920" />
    </Mention>
    <Mention id="M267" len="43" reason="from_drug_use" section="S3" start="2887" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Behavior abnormal" meddra_llt_id="10004203" meddra_pt="Abnormal behaviour" meddra_pt_id="10061422" />
    </Mention>
    <Mention id="M268" len="22,16" reason="class_effect" section="S3" start="2887,2935" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thought disorder" meddra_llt_id="10079962" meddra_pt="Thinking abnormal" meddra_pt_id="10043431" />
    </Mention>
    <Mention id="M199" len="18" reason="preexisting_condition_or_risk_factor" section="S3" start="2984" type="Not_AE_Candidate">
      <Normalization meddra_llt="Psychotic disorder" meddra_llt_id="10061920" meddra_pt="Psychotic disorder" meddra_pt_id="10061920" />
    </Mention>
    <Mention id="M269" len="5,41" reason="from_drug_use" section="S3" start="3108,3120" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bipolar affective disorder, manic" meddra_llt_id="10004919" meddra_pt="Bipolar I disorder" meddra_pt_id="10004939" />
    </Mention>
    <Mention id="M282" len="47" reason="class_effect" section="S3" start="3114" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bipolar affective disorder, manic" meddra_llt_id="10004919" meddra_pt="Bipolar I disorder" meddra_pt_id="10004939" />
    </Mention>
    <Mention id="M222" len="13" reason="AE_only_as_instruction" section="S3" start="3244" type="NonOSE_AE">
      <Normalization meddra_llt="Manic episode" meddra_llt_id="10026778" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M205" len="19" reason="preexisting_condition_or_risk_factor" section="S3" start="3288" type="Not_AE_Candidate">
      <Normalization meddra_llt="Depressive symptom" meddra_llt_id="10054089" meddra_pt="Depressive symptom" meddra_pt_id="10054089" />
    </Mention>
    <Mention id="M206" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="3331" type="Not_AE_Candidate">
      <Normalization meddra_llt="Suicide" meddra_llt_id="10042462" meddra_pt="Completed suicide" meddra_pt_id="10010144" />
    </Mention>
    <Mention id="M207" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="3340" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bipolar disorder" meddra_llt_id="10057667" meddra_pt="Bipolar disorder" meddra_pt_id="10057667" />
    </Mention>
    <Mention id="M208" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="3362" type="Not_AE_Candidate">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M270" len="9,8" reason="class_effect" section="S3" start="3466,3485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychotic symptom" meddra_llt_id="10079254" meddra_pt="Psychotic symptom" meddra_pt_id="10079254" />
    </Mention>
    <Mention id="M271" len="14" reason="class_effect" section="S3" start="3479" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Manic" meddra_llt_id="10026752" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M272" len="14" reason="class_effect" section="S3" start="3500" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hallucinations" meddra_llt_id="10019077" meddra_pt="Hallucination" meddra_pt_id="10019063" />
    </Mention>
    <Mention id="M273" len="19" reason="class_effect" section="S3" start="3516" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Delusional perception" meddra_llt_id="10012258" meddra_pt="Delusional perception" meddra_pt_id="10012258" />
    </Mention>
    <Mention id="M274" len="5" reason="class_effect" section="S3" start="3540" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M200" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="3601" type="Not_AE_Candidate">
      <Normalization meddra_llt="Psychotic" meddra_llt_id="10037248" meddra_pt="Psychotic disorder" meddra_pt_id="10061920" />
    </Mention>
    <Mention id="M201" len="5" reason="preexisting_condition_or_risk_factor" section="S3" start="3622" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M275" len="9,8" reason="class_effect" section="S3" start="3776,3795" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychotic symptom" meddra_llt_id="10079254" meddra_pt="Psychotic symptom" meddra_pt_id="10079254" />
    </Mention>
    <Mention id="M276" len="14" reason="class_effect" section="S3" start="3789" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Manic" meddra_llt_id="10026752" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M277" len="21" reason="from_drug_use" section="S3" start="3908" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth suppression" meddra_llt_id="10018761" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M278" len="11" reason="class_effect" section="S3" start="3974" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M279" len="22" reason="class_effect" section="S3" start="3990" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Growth retarded" meddra_llt_id="10018760" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M202" len="4" reason="indication" section="S3" start="4238" type="Not_AE_Candidate">
      <Normalization meddra_llt="ADHD" meddra_llt_id="10064104" meddra_pt="Attention deficit/hyperactivity disorder" meddra_pt_id="10003736" />
    </Mention>
    <Mention id="M254" len="18" reason="from_drug_use" section="S3" start="4269" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decrease" meddra_llt_id="10047893" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M223" len="11" reason="AE_only_as_instruction" section="S3" start="4322" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M212" len="33" reason="AE_for_another_drug_in_class" section="S3" start="4413" type="NonOSE_AE">
      <Normalization meddra_llt="Growth retardation" meddra_llt_id="10053759" meddra_pt="Growth retardation" meddra_pt_id="10053759" />
    </Mention>
    <Mention id="M255" len="23" reason="from_drug_use" section="S3" start="4602" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Poor peripheral circulation" meddra_llt_id="10036155" meddra_pt="Poor peripheral circulation" meddra_pt_id="10036155" />
    </Mention>
    <Mention id="M256" len="20" reason="from_drug_use" section="S3" start="4637" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Raynaud's phenomenon" meddra_llt_id="10037912" meddra_pt="Raynaud's phenomenon" meddra_pt_id="10037912" />
    </Mention>
    <Mention id="M224" len="18" reason="manifestation_or_complication" section="S3" start="4749" type="NonOSE_AE">
      <Normalization meddra_llt="Skin ulcer" meddra_llt_id="10040943" meddra_pt="Skin ulcer" meddra_pt_id="10040943" />
    </Mention>
    <Mention id="M225" len="21" reason="manifestation_or_complication" section="S3" start="4775" type="NonOSE_AE">
      <Normalization meddra_llt="Soft tissue disorder" meddra_llt_id="10061366" meddra_pt="Soft tissue disorder" meddra_pt_id="10061366" />
      <Normalization meddra_pt="Soft tissue injury" meddra_pt_id="10041291" />
    </Mention>
    <Mention id="M257" len="23" reason="from_drug_use" section="S3" start="4809" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Poor peripheral circulation" meddra_llt_id="10036155" meddra_pt="Poor peripheral circulation" meddra_pt_id="10036155" />
    </Mention>
    <Mention id="M258" len="20" reason="from_drug_use" section="S3" start="4844" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Raynaud's phenomenon" meddra_llt_id="10037912" meddra_pt="Raynaud's phenomenon" meddra_pt_id="10037912" />
    </Mention>
    <Mention id="M213" len="15" reason="AE_only_as_instruction" section="S3" start="5117" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M226" len="18" reason="AE_from_drug_interaction" section="S3" start="5311" type="NonOSE_AE">
      <Normalization meddra_llt="Serotonin syndrome" meddra_llt_id="10040108" meddra_pt="Serotonin syndrome" meddra_pt_id="10040108" />
    </Mention>
    <Mention id="M227" len="18" reason="AE_only_as_instruction" section="S3" start="6363" type="NonOSE_AE">
      <Normalization meddra_llt="Serotonin syndrome" meddra_llt_id="10040108" meddra_pt="Serotonin syndrome" meddra_pt_id="10040108" />
    </Mention>
    <Mention id="M228" len="21" reason="AE_only_as_instruction" section="S3" start="6403" type="NonOSE_AE">
      <Normalization meddra_llt="Mental status changes" meddra_llt_id="10048294" meddra_pt="Mental status changes" meddra_pt_id="10048294" />
    </Mention>
    <Mention id="M229" len="9" reason="AE_only_as_instruction" section="S3" start="6432" type="NonOSE_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M230" len="14" reason="AE_only_as_instruction" section="S3" start="6443" type="NonOSE_AE">
      <Normalization meddra_llt="Hallucinations" meddra_llt_id="10019077" meddra_pt="Hallucination" meddra_pt_id="10019063" />
    </Mention>
    <Mention id="M231" len="8" reason="AE_only_as_instruction" section="S3" start="6459" type="NonOSE_AE">
      <Normalization meddra_llt="Delirium" meddra_llt_id="10012218" meddra_pt="Delirium" meddra_pt_id="10012218" />
    </Mention>
    <Mention id="M232" len="4" reason="AE_only_as_instruction" section="S3" start="6473" type="NonOSE_AE">
      <Normalization meddra_llt="Coma" meddra_llt_id="10010071" meddra_pt="Coma" meddra_pt_id="10010071" />
    </Mention>
    <Mention id="M233" len="21" reason="AE_only_as_instruction" section="S3" start="6480" type="NonOSE_AE">
      <Normalization meddra_llt="Autonomic instability" meddra_llt_id="10049218" meddra_pt="Autonomic nervous system imbalance" meddra_pt_id="10003840" />
    </Mention>
    <Mention id="M234" len="11" reason="AE_only_as_instruction" section="S3" start="6509" type="NonOSE_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M235" len="21" reason="AE_only_as_instruction" section="S3" start="6522" type="NonOSE_AE">
      <Normalization meddra_llt="Blood pressure labile" meddra_llt_id="10005752" meddra_pt="Labile blood pressure" meddra_pt_id="10023533" />
    </Mention>
    <Mention id="M236" len="9" reason="AE_only_as_instruction" section="S3" start="6545" type="NonOSE_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M237" len="11" reason="AE_only_as_instruction" section="S3" start="6556" type="NonOSE_AE">
      <Normalization meddra_llt="Diaphoresis" meddra_llt_id="10012703" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M238" len="8" reason="AE_only_as_instruction" section="S3" start="6569" type="NonOSE_AE">
      <Normalization meddra_llt="Flushing" meddra_llt_id="10016825" meddra_pt="Flushing" meddra_pt_id="10016825" />
    </Mention>
    <Mention id="M239" len="12" reason="AE_only_as_instruction" section="S3" start="6579" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperthermia" meddra_llt_id="10020843" meddra_pt="Hyperthermia" meddra_pt_id="10020843" />
    </Mention>
    <Mention id="M240" len="22" reason="AE_only_as_instruction" section="S3" start="6594" type="NonOSE_AE">
      <Normalization meddra_llt="Neuromuscular toxicity" meddra_llt_id="10062284" meddra_pt="Neuromuscular toxicity" meddra_pt_id="10062284" />
      <Normalization meddra_pt="Neuromyopathy" meddra_pt_id="10029323" />
    </Mention>
    <Mention id="M241" len="6" reason="AE_only_as_instruction" section="S3" start="6624" type="NonOSE_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M242" len="8" reason="AE_only_as_instruction" section="S3" start="6632" type="NonOSE_AE">
      <Normalization meddra_llt="Rigidity" meddra_llt_id="10039168" meddra_pt="Muscle rigidity" meddra_pt_id="10028330" />
    </Mention>
    <Mention id="M243" len="9" reason="manifestation_or_complication" section="S3" start="6642" type="NonOSE_AE">
      <Normalization meddra_llt="Myoclonus" meddra_llt_id="10028622" meddra_pt="Myoclonus" meddra_pt_id="10028622" />
    </Mention>
    <Mention id="M244" len="13" reason="AE_only_as_instruction" section="S3" start="6653" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperreflexia" meddra_llt_id="10020745" meddra_pt="Hyperreflexia" meddra_pt_id="10020745" />
    </Mention>
    <Mention id="M245" len="14" reason="AE_only_as_instruction" section="S3" start="6668" type="NonOSE_AE">
      <Normalization meddra_llt="Incoordination" meddra_llt_id="10021649" meddra_pt="Coordination abnormal" meddra_pt_id="10010947" />
    </Mention>
    <Mention id="M246" len="8" reason="AE_only_as_instruction" section="S3" start="6685" type="NonOSE_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M247" len="25" reason="AE_only_as_instruction" section="S3" start="6702" type="NonOSE_AE">
      <Normalization meddra_llt="Gastrointestinal symptom NOS" meddra_llt_id="10018011" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M248" len="6" reason="AE_only_as_instruction" section="S3" start="6735" type="NonOSE_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M249" len="8" reason="AE_only_as_instruction" section="S3" start="6743" type="NonOSE_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M250" len="8" reason="AE_only_as_instruction" section="S3" start="6753" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M214" len="18" reason="AE_only_as_instruction" section="S3" start="6972" type="NonOSE_AE">
      <Normalization meddra_llt="Serotonin syndrome" meddra_llt_id="10040108" meddra_pt="Serotonin syndrome" meddra_pt_id="10040108" />
    </Mention>
    <Mention id="M251" len="18" reason="AE_only_as_instruction" section="S3" start="7310" type="NonOSE_AE">
      <Normalization meddra_llt="Serotonin syndrome" meddra_llt_id="10040108" meddra_pt="Serotonin syndrome" meddra_pt_id="10040108" />
    </Mention>
    <Mention id="M252" len="18" reason="AE_only_as_instruction" section="S3" start="7415" type="NonOSE_AE">
      <Normalization meddra_llt="Serotonin syndrome" meddra_llt_id="10040108" meddra_pt="Serotonin syndrome" meddra_pt_id="10040108" />
    </Mention>
  </Mentions>
</GoldLabel>